Cargando…

Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study

The mycolic acid biosynthetic pathway represents a promising source of pharmacological targets in the fight against tuberculosis. In Mycobacterium tuberculosis, mycolic acids are subject to specific chemical modifications introduced by a set of eight S-adenosylmethionine dependent methyltransferases...

Descripción completa

Detalles Bibliográficos
Autores principales: Galy, Romain, Ballereau, Stéphanie, Génisson, Yves, Mourey, Lionel, Plaquevent, Jean-Christophe, Maveyraud, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708032/
https://www.ncbi.nlm.nih.gov/pubmed/34959681
http://dx.doi.org/10.3390/ph14121282
_version_ 1784622583047520256
author Galy, Romain
Ballereau, Stéphanie
Génisson, Yves
Mourey, Lionel
Plaquevent, Jean-Christophe
Maveyraud, Laurent
author_facet Galy, Romain
Ballereau, Stéphanie
Génisson, Yves
Mourey, Lionel
Plaquevent, Jean-Christophe
Maveyraud, Laurent
author_sort Galy, Romain
collection PubMed
description The mycolic acid biosynthetic pathway represents a promising source of pharmacological targets in the fight against tuberculosis. In Mycobacterium tuberculosis, mycolic acids are subject to specific chemical modifications introduced by a set of eight S-adenosylmethionine dependent methyltransferases. Among these, Hma (MmaA4) is responsible for the introduction of oxygenated modifications. Crystallographic screening of a library of fragments allowed the identification of seven ligands of Hma. Two mutually exclusive binding modes were identified, depending on the conformation of residues 147–154. These residues are disordered in apo-Hma but fold upon binding of the S-adenosylmethionine (SAM) cofactor as well as of analogues, resulting in the formation of the short η1-helix. One of the observed conformations would be incompatible with the presence of the cofactor, suggesting that allosteric inhibitors could be designed against Hma. Chimeric compounds were designed by fusing some of the bound fragments, and the relative binding affinities of initial fragments and evolved compounds were investigated using molecular dynamics simulation and generalised Born and Poisson–Boltzmann calculations coupled to the surface area continuum solvation method. Molecular dynamics simulations were also performed on apo-Hma to assess the structural plasticity of the unliganded protein. Our results indicate a significant improvement in the binding properties of the designed compounds, suggesting that they could be further optimised to inhibit Hma activity.
format Online
Article
Text
id pubmed-8708032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87080322021-12-25 Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study Galy, Romain Ballereau, Stéphanie Génisson, Yves Mourey, Lionel Plaquevent, Jean-Christophe Maveyraud, Laurent Pharmaceuticals (Basel) Article The mycolic acid biosynthetic pathway represents a promising source of pharmacological targets in the fight against tuberculosis. In Mycobacterium tuberculosis, mycolic acids are subject to specific chemical modifications introduced by a set of eight S-adenosylmethionine dependent methyltransferases. Among these, Hma (MmaA4) is responsible for the introduction of oxygenated modifications. Crystallographic screening of a library of fragments allowed the identification of seven ligands of Hma. Two mutually exclusive binding modes were identified, depending on the conformation of residues 147–154. These residues are disordered in apo-Hma but fold upon binding of the S-adenosylmethionine (SAM) cofactor as well as of analogues, resulting in the formation of the short η1-helix. One of the observed conformations would be incompatible with the presence of the cofactor, suggesting that allosteric inhibitors could be designed against Hma. Chimeric compounds were designed by fusing some of the bound fragments, and the relative binding affinities of initial fragments and evolved compounds were investigated using molecular dynamics simulation and generalised Born and Poisson–Boltzmann calculations coupled to the surface area continuum solvation method. Molecular dynamics simulations were also performed on apo-Hma to assess the structural plasticity of the unliganded protein. Our results indicate a significant improvement in the binding properties of the designed compounds, suggesting that they could be further optimised to inhibit Hma activity. MDPI 2021-12-08 /pmc/articles/PMC8708032/ /pubmed/34959681 http://dx.doi.org/10.3390/ph14121282 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Galy, Romain
Ballereau, Stéphanie
Génisson, Yves
Mourey, Lionel
Plaquevent, Jean-Christophe
Maveyraud, Laurent
Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title_full Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title_fullStr Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title_full_unstemmed Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title_short Fragment-Based Ligand Discovery Applied to the Mycolic Acid Methyltransferase Hma (MmaA4) from Mycobacterium tuberculosis: A Crystallographic and Molecular Modelling Study
title_sort fragment-based ligand discovery applied to the mycolic acid methyltransferase hma (mmaa4) from mycobacterium tuberculosis: a crystallographic and molecular modelling study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708032/
https://www.ncbi.nlm.nih.gov/pubmed/34959681
http://dx.doi.org/10.3390/ph14121282
work_keys_str_mv AT galyromain fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy
AT ballereaustephanie fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy
AT genissonyves fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy
AT moureylionel fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy
AT plaqueventjeanchristophe fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy
AT maveyraudlaurent fragmentbasedliganddiscoveryappliedtothemycolicacidmethyltransferasehmammaa4frommycobacteriumtuberculosisacrystallographicandmolecularmodellingstudy